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a b s t r a c t
Schizophrenia (SCZ) and bipolar disorder (BPD) are severe heritable psychiatric disorders involving a
complex genetic aetiology. Neuregulin 1 (NRG1) is a leading candidate gene for SCZ, and has recently
been implicated in BPD. We previously reported association of two NRG1 haplotypes with SCZ and BPD
in a Scottish case–control sample. One haplotype is located at the 5′ end of the gene (region A), and
the other is located at the 3′ end (region B). Here, association to haplotypes within regions A and B was
assessed in patients with SCZ and BPD in a second Scottish case–control sample and in the two Scottish
samples combined. Association to region B was also assessed in patients with SCZ and BPD in a German
case–control sample, and in all three samples combined. No evidence was found for association in theeuregulin 1
ssociation study new samples when analysed individually; however, in the joint analysis of the two Scottish samples, a
region B haplotype comprising two SNPs (rs6988339 and rs3757930) was associated with SCZ and the
combined case group (SCZ: p=0.0037, OR=1.3, 95% CI: 1.1–1.6; BPD+SCZ: p=0.0080, OR=1.2, 95% CI:
1.1–1.5), with these associations withstanding multiple testing correction at the single-test level (SCZ:
pst = 0.022; BPD+SCZ: pst = 0.044). This study supports the involvement of NRG1 variants in the less well
studied 3′ region in conferring susceptibility to SCZ and BPD in the Scottish population.chizophrenia (SCZ) and bipolar disorder (BPD) are severe psy-
hiatric disorders, each affecting approximately 1% of the world’s
opulation. Family, twin, and adoption studies [5,24,25,37] support
strong genetic component to both disorders.
Neuregulin 1 (NRG1), located on chromosome 8p12, is a key
andidate susceptibility gene for SCZ [17], supported by genetic
∗ Corresponding author. Tel.: +44 0131 6511039.
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association studies [1,3,7,11,15,19,20,23,30,31,35,36,38,39,41,43]
(Fig. 1), meta-analyses [13,22,27,28], and functional plausibility
[10,17,26,42].More recently,NRG1 has been implicated in BPD, and
subgroups of BPD [11,12,14,31,39] (Fig. 1). This suggests that NRG1
polymorphisms may confer a wider susceptibility to psychiatric
illness.
Recently, we reported the association of haplotypes in two
regions, A and B, of NRG1 with SCZ and/or BPD in a Scottish
′case–control sample [39] (Fig. 1). RegionA,which is located at the5
endof the gene and includes thepromoter region,was found tohar-
bour a rare three-SNP haplotype associated with SCZ (p=0.00032)
and the combined SCZ and BPD case group (p=0.0017). Region B,
which is located at the 3′ end of the gene and spans the sensory and



































Pig. 1. Most signiﬁcant individual haplotype p-values fromprevious association stud
s indicatedby its locationon the y-axis and the genomicpositionof thehaplotype, ac
re within chromosome 8p12.
otor neuron derived factor isoform, contained a common three-
NP haplotype associated with both SCZ and BPD (p=0.000062).
Here, we sought to replicate our previous ﬁndings by assessing
he association of regions A and B to SCZ and/or BPD in a second
cottish case–control sample (Scottish 2). Association to region B,
he more signiﬁcant of the two regions, was also assessed in a
erman case–control sample. In addition, two joint analyses were
arried out, ﬁrst combining the two Scottish samples (Merged Scot-
ish) and then all three samples (Merged All). Approval to conduct
his research was obtained from the Scotland A Research Ethics
ommittee.
The Scottish 1 case–control sample has been described previ-
usly [39]. For the Scottish 2 sample, individuals diagnosed with
PD or SCZ (Supplementary Table 1) were recruited from inpatient
nd outpatient services at psychiatric hospitals in South-East and
outh-Central Scotland, and from Ravenscraig Hospital, Greenock,
nverclyde. Diagnoses were reached by consensus between two
sychiatrists according to the Diagnostic and Statistical Manual of
ental Disorders (4th edition) (DSM–IV) [2] on the basis of medi-
al and psychiatric histories, case note review, and interview using
he Schedule for Affective Disorder and Schizophrenia—Lifetime
ersion (SADS-L) [9].
Control subjects in the Scottish 2 sample were recruited from
he same population in South-East and South-Central Scotland and
rom the Grampian region of Scotland, with the majority (>80%)
ecruited through the Scottish National Blood Transfusion Service,
hich only accepts individuals who are not currently taking med-
cation and do not have a chronic illness. The rest were recruited
rom hospital staff or the general population, and were screened
o exclude anyone currently taking medication or with a history of
sychiatric illness.TheGermancase–control sample (Supplementary Table 1) com-
rised individualswith a lifetimediagnosis of BPDor SCZ, according
o DSM-IV criteria, who were recruited from consecutive admis-
ions to the inpatient unit of the Department of Psychiatry and
sychotherapy of the University of Bonn and of the Central Insti-NRG1 and schizophrenia and/or bipolar disorder. The signiﬁcance of each haplotype
g toNCBI build 36, is indicatedbypositionon the x-axis. All SNPs andmicrosatellites
tute of Mental Health in Mannheim. Final diagnoses were reached
using a consensus best estimate procedure [21], based on med-
ical records, family history, and information obtained through a
structured clinical interview for DSM-III-R (SCID-I) [34].
German control subjectswere recruited from the Bonn region of
Germany. Both the patient and the control sampleswere of German
ancestry, extending back at least three generations.
Genotyping of the Scottish 1 sample has been described previ-
ously [39]. Genotypingof the three regionAand three regionBSNPs
in the Scottish 2 samplewas carried out at theWellcomeTrust Clin-
ical Research Facility, Edinburgh, UK, using the Illumina BeadArray
platform. The three region B SNPs were genotyped in the German
sample using the Illumina BeadArray platform at the University of
Bonn, Germany.
For both case–control samples, SNPs with a locus success rate
of <90% and samples with a genotyping success rate of <90% were
excluded from the analyses. Following these quality control mea-
sures, genotype data was available for ﬁve SNPs (three region A
SNPs and two region B SNPs) in 307 control, 303 SCZ, and 239 BPD
subjects in the Scottish 2 sample, and for the three region B SNPs in
397 control, 396 SCZ, and 400 BPD subjects in the German sample
(Supplementary Table 1).
All SNPs were assessed for deviation from Hardy–Weinberg
equilibrium (HWE) using a 2 goodness-of-ﬁt test, with p≤0.05.
None of the SNPs deviated from HWE (p≥0.065). In order to
assess the effect of biases such as population differences prior to
combining samples for the merged analyses, the genetic homo-
geneity of the three control groups was assessed using the 2
test-of-independence. None of the SNPs were found to differ sig-
niﬁcantly between the three control groups (corrected pst ≥0.053;
Supplementary Table 2).Differences in allele and genotype frequencies between cases
and controls were assessed using the 2 test-of-independence.
Haplotype frequency estimation and comparisons between cases
and controls were carried out using Cocaphase 2.404 [8]. Haplo-
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frequency of less than 1% in cases and controls were grouped for
he global test of signiﬁcance. Odds ratios (ORs) and 95% conﬁdence
ntervals (CIs) were calculated using the most common haplotype
n the control sample as the reference. When the most common
aplotype was the haplotype of interest, the second most common
aplotype was used as the reference.
Associations directly replicating those identiﬁed in the anal-
sis of the Scottish 1 sample [39] were accepted as signiﬁcant
hen p≤0.05, due to the a priori evidence for these SNPs. In the
eparate analysesof theScottish2andGermansamples, novel asso-
iations attaining nominal signiﬁcance (p≤0.05) were corrected
y permutation analysis. In the merged analyses, all nominally
igniﬁcant associations were corrected by permutation analysis.
ermutation analysis (1000 permutations) was performed using
ocaphase 2.404. Corrections were made at two levels: the single-
est level (pst) and the experiment-wise level (pew; Supplementary
able 3). The single-test level corrects for multiple comparisons
ithin a particular subgroup and region, at the single-marker
r haplotype level. The experiment-wise level combines p-values
cross diagnostic groups (SCZ, BPD, and combined), and single-
arker and haplotype tests to give a regionally corrected p-value
ithin each sample. No correction was made for the use of allelic
nd genotypic tests, as these tests are highly correlated. Permu-
ation analysis was chosen as the method of choice for multiple
esting correction as it offers correction suitable for datasets of
on-independent variables, such as SNPs in linkage disequilibrium
29].
In the separate sample analyses of the Scottish 2 and German
amples, none of the SNPs, or two- or three-marker haplotypes
ithin either region A or region B were signiﬁcantly associated
ith SCZ, BPD, or the combined case group in the Scottish 2 sample
best uncorrected p-value =0.14; Table 1). In the German sample,
he only signiﬁcant association was to a three-SNP region B haplo-
ype (C-A-C) in BPD cases at the individual (uncorrected pi = 0.020)
ut not global (uncorrected pg = 0.35) level (Table 1). However, fol-
owing correction by permutation analysis the individual p-value
as not statistically signiﬁcant (corrected pst = 0.13).
In the combined analyses, the only signiﬁcant single-marker
ssociation was between the intronic region B SNP rs6988339 and
CZ in the Merged Scottish sample (uncorrected p=0.024; Table 1).
owever, this association did notwithstand correction formultiple
esting (corrected pst = 0.059).
The three-SNP region A haplotype (T-T-T; Table 1;
upplementary Table 3), which was nominally associated with
CZ in the initial Scottish sample, was signiﬁcantly associated with
CZ in the Merged Scottish sample (Scottish 1 and Scottish 2) at
he individual level (uncorrected pi = 0.028), however this did not
urvive multiple testing correction (corrected p=0.21). In contrast
o the Scottish 1 sample, this haplotype was not associated with
he combined case group.
In keeping with ﬁndings in the Scottish 1 sample [39], the
wo-SNP region B haplotype (Table 1; Supplementary Table 3)
omprising SNPs rs6988339 and rs3757930 (G-C) was signiﬁ-
antly associated with SCZ and the combined case group in the
erged Scottish analysis, in both the individual (SCZ: uncorrected
i = 0.0037; BPD+SCZ: uncorrected pi = 0.0080) and global (SCZ:
ncorrected pg = 0.030; BPD+SCZ: uncorrected pg = 0.029) haplo-
ype tests. These associations remained signiﬁcant after correction
f individual p-values by permutation analysis (SCZ: corrected
st = 0.022; BPD+SCZ: corrected pst = 0.044). This haplotype was
ore common in cases (SCZ: 32.9%, BPD+SCZ: 32.0%) than controls27.3%), conferring an increased disease risk (SCZ: OR=1.3, 95% CI:
.1–1.6; BPD+SCZ: OR=1.2, 95% CI: 1.1–1.5). This haplotype was
lso associated with the combined case group in the Merged All
roup in the individual (uncorrected pi = 0.045) but not the global
uncorrected pg = 0.11) test of signiﬁcance. The association in theLetters 478 (2010) 9–13 11
MergedAll groupdidnot remain signiﬁcant after permutationanal-
ysis (corrected pst = 0.16).
To compensate for the genotyping failure of one of the region B
SNPs in theScottish2 sample, the ability of the two-SNP (rs6988339
and rs3757930) region B haplotype to predict the three-SNP region
B haplotype was assessed in the Scottish 1 sample. Genotype
data was uploaded to Haploview 4.2 and linkage disequilibrium
between the two- and three-SNP region B haplotypes calculated.
The two-SNP G-C haplotype, which was signiﬁcant in the Scottish 2
sample,was found topredict the three-SNPA-G-Chaplotype,which
was signiﬁcantly associated with SCZ and the combined case group
in our original study [39], with an r2 >0.95 (Supplementary Fig. 1).
It therefore seems likely that the same three-SNP haplotype would
show signiﬁcant association in the Scottish 2 sample.
In this study, individual analysis of the two new case–control
samples failed to replicate any of our previously reported associ-
ations [39]. However, on combining the two Scottish samples, a
two-SNPhaplotype in regionB (rs6988339and rs3757930)was sig-
niﬁcantly associated with SCZ and the combined case group, with
these associations surviving correction for multiple testing at the
single-test, but not experiment-wise, level of permutation analysis.
One interpretation of these results is that NRG1 risk variants are
genetically heterogeneous amongst cases from different popula-
tions. Heterogeneity amongst different European populations has
been demonstrated for another SCZ- and BPD-risk gene,DISC1 [18].
To investigate this heterogeneity, Hennah et al. [18] used condi-
tional association analysis to detect DISC1 variants that confer risk
only on certain genetic backgrounds.
Furthermore, SCZ and BPD are likely to be phenotypically het-
erogeneous. The broad diagnostic categories of SCZ and BPD used
to select cases in this study may have obscured a difference in the
phenotypic composition of the individual case–control samples.
Variants in NRG1 may be involved in certain sub-phenotypes of
SCZ and BPD. Indeed, studies have already demonstrated associa-
tion of NRG1 variants with particular aspects of psychiatric illness,
including the development of psychotic symptoms, and abnormal
P300 electroencephalogram activation [4,12,16,31,33].
An important caveat is the issue of sample size and its corollary,
statistical power. In the larger merged Scottish sample we increase
power and detect association with a reduced OR, consistent with
results from genome wide association studies [6]. Estimates of
effect size in the original study are, therefore, probably inﬂated,
following the winner’s curse phenomenon [40]. This suggests that
the two new samples may have been underpowered to detect a
variant of small effect size.
Power to detect the two-SNP (rs6988339 and rs3757930) region
B haplotype in the SCZ and combined case groups in the Scottish
2 and German samples, assuming the same effect size as identi-
ﬁed in the merged Scottish sample, was assessed using an online
genetic power calculator [32]. These calculations indicated approx-
imately 90% power (uncorrected p≤0.05) to detect this haplotype
in all groups (Supplementary Table 4). However, the validity of
these calculations is limited by the need to assume complete link-
age equilibrium between the genotyped marker(s) and the risk
allele(s); this is unlikely to be true. Furthermore, following correc-
tion for multiple testing, power to detect differences at adjusted
p-values will be less than predicted.
In summary, in this study we have found no evidence for asso-
ciation to region A and shown support for the presence of a risk
variant for SCZ and/or BPD within, or in LD with, region B in an
enlarged case–control sample. These ﬁndings contribute to a sub-
stantial body of genetic and functional evidence supporting the
candidacy of NRG1 as a SCZ- and BPD-susceptibility gene. Taking
into consideration the issues of genetic and phenotypic hetero-
geneity, and sample size, it seems that our understanding of NRG1
would bemost successfully expanded through association analyses
12 R.M. Walker et al. / Neuroscience Letters 478 (2010) 9–13
Table 1
Individual association analysis results for single-, two-, and three-marker haplotypes.
Marker (NCBI build 36 position) Best individual haplotype p-values
SCZ BPD Combined SCZ and BPD
Single Two Three Single Two Three Single Two Three
Region A
rs1503491 (chr8:31761648)
Scottish 1 0.61 0.024 0.00032 0.24 0.037 0.084 0.70 0.012 0.0017
Scottish 2 0.94 0.87 0.61 0.61 0.79 0.57 0.83 0.81 0.57
Merged Scottish 0.86 0.096 0.028 0.51 0.14 0.69 0.79 0.067 0.098
rs553950 (chr8:31910904)
Scottish 1 0.028 0.0085 0.028 0.044 0.012 0.052
Scottish 2 0.99 0.68 0.95 0.30 0.96 0.31
Merged Scottish 0.093 0.074 0.11 0.058 0.058 0.27
rs327329 (chr8:31973040)
Scottish 1 0.44 0.85 0.74
Scottish 2 0.99 0.58 0.78
Merged Scottish 0.56 0.85 0.65
Region B
rs2919390 (chr8:32646497)
Scottish 1 0.010 0.0012 0.00014 0.080 0.014 0.0022 0.010 0.00084 0.000062
German 0.92 0.31 0.17 0.073 0.12 0.24 0.33 0.74 0.93
rs6988339 (chr8:32665458)
Scottish 1 0.010 0.0014 0.032 0.0045 0.0059 0.00044
Scottish 2 0.55 0.48 0.14 0.45 0.69 0.96
German 0.38 0.26 0.19 0.34 0.80 0.93
Merged Scottish 0.024 0.0037 0.55 0.072 0.087 0.0080
Merged all 0.22 0.098 0.19 0.072 0.14 0.045
rs3757930 (chr8:32708660)
Scottish 1 0.20 0.16 0.12
Scottish 2 0.69 0.57 0.58
German 0.16 0.35 0.18
Merged Scottish 0.17 0.17 0.11
Merged all 0.85 0.70 0.74
G - and
c [39] a




















tlobal p-values are shown for each SNP and individual haplotype p-values for two
ombined case group (combined SCZ and BPD). Results from the Scottish 1 sample
ach multi-marker haplotype. Associations attaining nominal signiﬁcance (p≤0.05
re highlighted in bold.
f larger genetically and/or phenotypically homogenous samples,
nd interaction analyses to determine the effect of NRG1 variants
n speciﬁc genetic backgrounds.
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